

# Discovery of hit/lead compounds for sepsis treatment targeting ASM pathogenesis via immune and intestinal barrier permeability mechanisms



OTHERS	Hit
Product Type	Small molecules
Indication	Sepsis
Target	Acid sphingomyelinase (ASM)
MoA(Mechanism of Action)	Small molecule inhibitor targeting ASM → Reduction in inflammatory cytokine production → Reduction in immune-intestinal barrier permeability → Targeted therapy for sepsis
Competitiveness	<ul style="list-style-type: none"> <li>• First-in-Class</li> <li>• Infection-induced upregulation of acid sphingomyelinase(ASM) in circulating monocytes promotes gut barrier permeability by increasing inflammatory cytokine production and reducing epithelial integrity, representing a novel pathogenic mechanism in sepsis and a promising target for therapeutic development.</li> </ul>
Development Stage	Hit
Route of Administration	Intravenous injection (IV) Intraperitoneal injection (IP)

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*